



Zyclara filed in Europe

The marketing authorization application for the patented product Zyclara (imiquimod 3.75% cream) has been filed with the European Medicines Agency (EMA). Zyclara has been documented for once-daily topical treatment of actinic keratosis (AK).

Zyclara expands the treatment area to the full face or balding scalp and could become a first line therapy for AK. More than 1,400 patients have been included in seven clinical studies.

“Zyclara will strengthen Meda’s dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”, says Anders Lönner, CEO of Meda.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.